Aimmune Therapeutics Inc. (NASDAQ:AIMT) was up 4.8% on Monday . The company traded as high as $13.59 and last traded at $13.50, with a volume of 53,211 shares trading hands. The stock had previously closed at $12.88.

A number of equities research analysts recently weighed in on AIMT shares. Piper Jaffray Cos. reaffirmed an “overweight” rating and set a $38.00 price objective on shares of Aimmune Therapeutics in a research report on Wednesday, June 29th. Zacks Investment Research lowered Aimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, July 19th. Wedbush reissued an “outperform” rating and issued a $42.00 price objective on shares of Aimmune Therapeutics in a report on Wednesday, August 10th. Finally, Bank of America Corp. reissued a “buy” rating on shares of Aimmune Therapeutics in a report on Monday, May 16th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $33.40.

The stock’s market cap is $549.30 million. The stock has a 50 day moving average price of $11.65 and a 200 day moving average price of $13.80.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its quarterly earnings data on Wednesday, August 10th. The company reported ($0.43) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.42) by $0.01. On average, equities research analysts predict that Aimmune Therapeutics Inc. will post ($1.71) EPS for the current fiscal year.

In other Aimmune Therapeutics news, major shareholder Foresite Capital Fund Ii, L.P. sold 240,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 31st. The stock was sold at an average price of $15.23, for a total transaction of $3,655,200.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

A hedge fund recently raised its stake in Aimmune Therapeutics stock. Aisling Capital LLC raised its position in Aimmune Therapeutics Inc. (NASDAQ:AIMT) by 6.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,990,000 shares of the company’s stock after buying an additional 170,000 shares during the period. Aimmune Therapeutics makes up 9.5% of Aisling Capital LLC’s investment portfolio, making the stock its 4th largest position. Aisling Capital LLC owned approximately 7.08% of Aimmune Therapeutics worth $55,166,000 as of its most recent filing with the SEC.

Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.